Finally, the strongest effect was noted in the combination of MRK-560 with nuclear export inhibitor KPT-8602, which makes it possible to obtain the maximum treatment effect in the largest possible cohort, since the majority of T-ALL cases harbor NOTCH1 pathway mutations and no specific mutations are required for sensitivity toward KPT-8602. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.